Takeda Considers Research Facility in India (India)
This article was originally published in PharmAsia News
Japan's largest drug maker, Takeda, is expected to emulate fellow drug makers Daiichi Sankyo and Esai in locating research facilities in India to take advantage of lower costs. Takeda is said to be hunting for someone familiar with India to head a new division in the country. Daiichi opened an India operation in 2007 and Esai created Esai Pharmaceuticals India subsidiary. Takeda is expected to reach a final decision this year and start off with one or two products. (Click here for more
You may also be interested in...
In a 1 June speech before the Alliance For a Stronger FDA, US FDA commissioner Stephen Hahn stressed the agency’s vigilance in guarding against consumer use of flawed COVID-19 products. He also made comments about the need for doctors to communicate more with patients. See what he said about the use of telehealth here.
Request for documents and a briefing is part of efforts to ensure federal programs are ‘protected from price gouging.’
Merck’s Frazier Urges Businesses To Use ‘Every Instrument At Their Disposal’ To Reduce Racial Inequity
‘What we have to guard against is that when the streets quiet down … a lot of people are going to go back to their normal lives,’ Merck CEO Ken Frazier says in an interview with CNBC.